Abstract
Comparing patients with primary hyperparathyroidism (PHP) to a normocalcemic control population, those with PHP have a higher incidence of cardiovascular disease and cardiac abnormalities. This study aimed at correlating cardiac findings (valvular and myocardial calcification, myocardial hypertrophy) with clinical data (age, sex, clinical manifestation, nephrolithiasis, nephrocalcinosis, hypertension, skeletal abnormalities, hypercalcemic syndrome) and biochemical data (serum calcium, serum phosphate, serum iPTH level, serum creatinine). A group of 132 consecutive patients with surgically verified PHP (94 women, 38 men; ages 15–86, mean age 57±16 years) were included in this study. Blood chemistry, clinical presentation, radiography, and echocardiography were carried out in all patients for univariate and multivariate analyses of all parameters. There was no statistical correlation between clinical symptoms, biochemical data, and cardiac calcific alterations. Typical skeletal manifestations (osteolysis/subperiostal resorption) and valvular calcifications were significantly correlated to left ventricular hypertrophy (p=0.005). Cardiac abnormalities such as calcific myocardial deposits or mitral and aortic valvular calcifications do not correlate with laboratory findings and clinical presentation at the time of diagnosis. There was no biochemical or clinical variable that could predict the frequency or severity of valvular sclerosis or calcific deposits in the myocardium. However, PHP-related skeletal abnormalities and valvular calcification were predicting factors for left ventricular hypertrophy, a reversible cardiac manifestation of PHP. Myocardial hypertrophy is more often found with classic symptomatic PHP with osseous abnormalities.
Résumé
Les patients ayant une hyperparathyroïdie primitive (HPP) ont plus de maladies cardiovasculaires que la population normocalcémique. Le but de cette étude a été de corréler les données cardiaques (calcifications myocardiques et valvulaires, hypertrophie myocardiques) avec des données cliniques (âge, sexe, manifestations cliniques, lithiase urinaire, néphrocalcinose, hypertension, anomalies squelettiques, hypercalcémie) et biochimiques (calcémie, phosphorémie, taux d'iPTH, créatinine). 132 patients consécutifs traités pour HPP 94 femmes et 38 hommes, âgés de 15 à 86 (moyenne = 57±16) ans ont eu ce bilan et tous ces facteurs ont été étudiés en analyse mono et multi-factorielle. Il n'a pas été retrouvé de corrélation entre les symptômes cliniques, biochimiques et les calcifications cardiaques. Les manifestations squelettiques typiques (ostéolyse/résorption souspériostée) et les calcifications valvulaires étaient significativement corrélées avec l'hypertrophie ventriculaire gauche (p=0.005). Les anomalies cardiaques telles que les calcifications myocardiques, valvulaires mitrales et/ou aortiques ne sont pas corrélées avec les données de laboratoire ou la présentation clinique au moment du diagnostic. Il n'y avait aucun variable clinique ou biochimique qui prédise la fréquence ou la sévérité de la sclérose valvulaire ou les calcifications myocardiques. Les anomalies squelettiques et calcifications valvulaires, cependant, étaient prédictives d'hypertrophie ventriculaire gauche, une complication réversible de l'HPP. L'hypertrophie myocardique est retrouvée plus souvent dans la forme classique d'HPP symptomatique avec des anomalies osseuses.
Resumen
Al comparar pacientes con hiperatiroidismo primario (HPP) con personas pertenecientes a una población normal control, aparece que en el HPP hay una mayor incidencia de enfermedad cardiovascular y de anormalidades cardíacas. El presente estudio está orientado a correlacionar los hallazgos cardíacos (calcificación valvular y miocárdica, hipertrofia miocárdica) con las características clínicas (edad, sexo, manifestación clínica, nefrolitiasis, nefrocalcinosis, hipertensión, anormalidades del esqueleto, síndrome hipercalcémico) y los datos bioquímicos (calcio sérico, fosfato sérico, nivel sérico de iHPT, creatinina sérica).
Ciento treinta y dos pacientes con HPP verificado quirúrgicamente 94 mujeres y 38 hombres con edades entre 15 y 86 (media 57±16) años fueron incorporados en el estudio, con la inclusión, para análisis uni y multivariable, de la química sanguínea, síntomas de presentación clínica, radiografía y ecocardiografía.
No apareció correlación estadística entre los síntomas clínicos, los datos bioquímicos y las alteraciones de calcificación cardíaca. Las manifestaciones esqueléticas (osteolisis/resorción subperióstica) y las calcificaciones valvulares aparecieron significativamente correlacionadas con la hipertrofia ventricular izquierda (p=0.005).
En conclusión, las anormalidades cardíacas tales como depósitos calcíficos en el miocardio, calcificaciones valvulares mitrales y/o aórticas no se correlacionan ni con los valores de laboratorio ni con los síntomas de presentación clínica en el momento del diagnóstico. No se encontró variable alguna, bioquímica o química, que pudiera predecir la frecuencia o la severidad de la esclerosis valvular o de los depósitos calcíficos en el miocardio. Sin embargo, tanto las anormalidades esqueléticas como la calcificación valvular aparecieron como factores de predicción de la hipertrofia ventricular izquierda, la cual es una manifestación reversible del HPP. La hipertrofia miocárdica se presenta con mayor frecuencia en un HPP clásico con anormalidades óseas.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Ronni-Sivula, H.: The state of health of patients previously operated on for primary hyperparathyroidism compared with randomized controls. Ann. Chir. Gynaecol. 74:60, 1985
Palmer, M., Adami, H.O., Bergström, R., Akerström, G., Ljunghall, S.: Mortality after surgery for primary hyperparathyroidism: a follow-up of 441 patients operated on from 1956 and 1979. Surgery 102:1, 1987
Ronni-Sivula, H.: Causes of death in patients previously operated for primary hyperparathyroidism. Ann. Chir. Gyneocol. 74:13, 1985
Ronni-Sivula, H., Sivula, A.: Long-term effect of surgical treatment on the symptoms of primary hyperparathyroidism. Ann. Clin. Res. 17:141, 1985
Niederle, B., Roka, R., Woloszczuk, W., Klaushofer, K., Kovarik, J., Schernthaner, G.: Successful parathyroidectomy in primary hyperparathyroidism: a clinical follow-up study of 212 consecutive patients. Surgery 102:903, 1987
Hedbäck, G., Tisell, L.E., Bentsson, B.A., Hedman, I., Oden, A.: Premature death in patients operated on for primary hyperparathyroidism World J. Surg. 14:829, 1990
Palmer, M., Bergström, G., Adami, H.O., Jakobsson, S., Ljunghall, S.: Survival and renal function in untreated hypercalcemia, population-based cohort study with 14 years follow-up. Lancet 1:59, 1987
Lind, L., Jacobsson, S., Palmer, M., Lithell, H., Wengle, B., Ljunghall, S.: Cardiovascular risk factors in primary hyperparathyroidism: a 15-year follow-up of operated and unoperated cases. J. Intern. Med. 230:29, 1991
Lafferty, F.W.: Primary hyperparathyroidism: changing clinical spectrum, prevalence of hypertension and discriminant analysis of laboratory tests. Arch. Intern. Med. 141:1761, 1981
Kesteloot, H., Geboers, J.: Calcium and blood pressure. Lancet 1:813, 1982
Nainby-Luxmoore, J.C., Langford, H.G., Nelson, N.C., Watson, R.L., Barnes, T.Y.: A case-comparison study of hypertension and hyperparathyroidism. J. Clin. Endocrinol. Metab. 55:303, 1982
Rapado, A.: Arterial hypertension and primary hyperparathyroidism: incidence and follow-up after parathyroidectomy. Am. J. Nephrol. 6(Suppl. 1):49, 1986
Symons, C., Fortune, F., Greenbaum, R.A., Dandona, P.: Cardiac hypertrpophic cardiomyopathy and hyperparathyroidism—an association. Br. Heart J. 54:539, 1985
Janssens, S., DeGeest, H., Decramer, M.: Hypetrophic cardiomyopathy caused by hyperparathyroidism: report of a case and review of the literature. Acta Cardiol. 12:287, 1987
Diamond, T.H., Kawalsky, D.L., van der Merwe, T.L., Myburgh, D.P.: Hypercalcaemia due to parathyroid adenoma and hypertrophic cardiomyopathy: a case report. S. Afr. Med. J. 71:448, 1987
Harnet, J.D., Parfrey, P.S., Griffiths, S.M., Gault, M.H., Barre, P., Guttmann, R.D.: Left ventricular hypertrophy in end-stage renal disease. Nephron 18:107, 1988
Roberts, W.C., Waller, B.F.: Effects of chronic hypercalcemia on the heart. Am. J. Med. 71:371, 1981
Herrmann, G., Hehrmann, R., Scholc. H.C., et al.: Parathyroid hormone in coronary artery disease—result of a prospective study. J. Endocrinol. Invest. 9:265, 1986
Nestico, P.F., dePace, N.L., Kotler, M.N., et al.: Calcium phosphorus metabolism in dialysis patients with and without mitral anular calcium: analysis of 30 patients. Am. J. Cardiol. 51:497, 1983
Maher, E.R., Young, G., Smyth-Walsh, B., Pugh, S., Curtis, J.R.: Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet 2:875, 1987
Niederle, B., Stefenelli, T., Glogar, D., Woloszczuk, W., Roka, R., Mar, H.: Cardiac calcific deposits in patients with primary hyperparathyroidism: preliminary results of an echocardiographic study. Surgery 108:1052, 1990
Glogar, D., Zilcher, H., Lintner, F., Kern, H.G., Willvonseder, R.: Calcium-induced necrosis of cardiac muscle causing death in acute hyperparathyroidism. Dtsch. Med. Wochenschr. 105:1, 1980
Rayner, H.C., Hoskind, D.J.: Hyperparathyroidism associated with severe hypercaemia and myocardial calcification despite minimal bone disease. B.M.J. 293:1277, 1986
Sanders, C., Frank, M.S., Rostand, S.G., Rutsky, E.A., Barnes, G.T., Fraser, R.G.: Metastatic calcification of the heart and lungs in end-stage renal disease: detection and quantification by dualenergy digital chest radiography. Am. J. Radiol. 149:881, 1987
Katz, J.H., Dias, S.M., Ferguson, R.P.: Fatal cardiac calcifications secondary to primary hyperparathyroidism. Am. J. Med. 85:122, 1988
Catellier, M.J., Chua, G.T., Youmans, G., Waller, B.F.: Calcific deposits in the heart. Clin. Cardiol. 13:287, 1990
Stefenelli, T., Wikman-Coffelt, J., Wu, S.T., Parmley, W.W.: Calcium-dependent fluorescence transient during ventricular fibrillation. Am. Heart J. 120:590, 1990
Bondeson, A.G., Thompson, N.W., Santinga, J., Bondeson, L.: Coronary artery disease in primary hyperparathyroidism. In Abstracts of the 34th World Congress of Surgery, 1991
Niederle, B., Roka, R., Fritsch, A.: Long-term results after surgical treatment of primary hyperparathyroidism. Prog. Surg. 18:146, 1986
Lafferty, F.W., Hubay, C.A.: Primary hyperparathyroidism: a review of the long-term surgical and nonsurgical morbidities as a basis for rational approach to treatment. Arch. Intern. Med. 149:789, 1989
McCarron, D.A., Pingree, P.A., Robin, R.J., Gander, S.M., Molitch, M., Krutzik, S.: Enhanced parathyroid function in essential hypertension. Hypertension 2:162, 1980
Shaw, J., Croxon, M., Holdaway, I., Collins, J., Wolfe, R.: Glucose, fat, and protein kinetics and patients with primary and secondary hyperparathyroidism. Surgery 103:526, 1988
Prager, R., Schernthaner, G., Niederle, B., Roka, R.: Evaluation of glucose tolerance, insulin secretion and insulin action in patients with primary hyperparathyroidism before and after surgery. Calcif. Tissue Int. 46:1, 1990
Stefenelli, T., Mayr, H., Bergler-Klein, J., Globits, S., Woloszczuk, W., Niederle, B.: Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am. J. Med. 95:197, 1993
Dalberg, K., Brodin, L.A., Juhlin-Dannefelt, A., Farnebo, L.O.: Cardiac calcifications in primary hyperparathyroidism. [abstract 332]. In International Surgical Week. Hong Kong, 1993
Hedbäck, G., Oden, A., Tisel, L.: The influence of surgery on death in patients with primary hyperparathyroidism. World J. Surg. 15:399, 1991
Terman, D.S., Alfrey, A.C., Hammond, W.A.S., Donndelinger, T., Ogden, D.A., Holmes, J.H.: Cardiac calcification in uremia. Am. J. Med. 50:744, 1971
Slavich, G.A., Antonucci, F., Sponza, E.: Primary hyperparathyroidism and angina pectoris. Int. J. Cardiol. 19:266, 1988
Palmieri, G.M.A., Nutting, D.F., Bhattacharya, S.K., Betorini, T.E., Williams, J.C.: Parathyroid ablation in dystrophic hamsters: effect on Ca content and histology of heart, diaphragm, and rectus femoris. J. Clin. Invest. 68:646, 1981
Nickols, G.A.: Action of parathyroid hormone in the cardiovascular system. Blood Vessels 24:120, 1987
Stefenelli, T.: The importance of intracellular calcium homeostasis in contraction and relaxation of the heart muscle. Wien. Klin. Wochenschr. 104:5:111, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Längle, F., Abela, C., Koller-Strametz, J. et al. Primary hyperparathyroidism and the heart: Cardiac abnormalities correlated to clinical and biochemical data. World J. Surg. 18, 619–624 (1994). https://doi.org/10.1007/BF00353780
Issue Date:
DOI: https://doi.org/10.1007/BF00353780